U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

BioMarin said the FDA accepted its supplemental NDA for VOXZOGO (vosoritide) for full approval in children with achondroplasia, with a PDUFA target action date of Feb. 28, 2027. The sNDA is supported by long-term data from three ongoing studies and includes additional clinical outcomes beyond linear growth, such as body proportionality and arm span. If approved, VOXZOGO would be the first achondroplasia therapy to convert from accelerated approval to traditional approval on a comprehensive long-term package.

Analysis

For BMRN, this is more about lowering the discount rate on an existing cash flow than creating a brand-new growth vector. Full approval would matter because it converts a niche orphan franchise from "possible durability" to "durability with regulatory validation," which can support a higher EV/revenue multiple even if near-term prescriptions barely change. The bigger operating lever is payer behavior: chronic, caregiver-administered therapies are highly sensitive to prior-auth friction and confidence in long-term benefit, so label conversion can improve persistence and earlier initiation more than it expands the addressable pool.

The catalyst path is long and uneven. The first leg is sentiment-only; the real checkpoints are interim long-term data updates over the next 6-12 months and the FDA decision in early 2027. What can break the thesis is not a lack of growth velocity alone, but any FDA view that adult-height/proportionality data still do not translate into sufficiently meaningful clinical benefit, or any safety/adherence issue that makes payers and prescribers question chronic use. If those don’t materialize, the approval likely removes an overhang, but the rerating should be modest rather than dramatic.

Contrarian view: the market may be overpricing the upside from a title change while underpricing the moat from BioMarin’s service infrastructure. The durable advantage is the installed physician network, caregiver training, and the fact that this remains the only meaningful commercial standard in the category; that can defend share even if future FGFR3-pathway entrants appear later. Still, this is not a broad biotech read-through: the signal is specific to BMRN, and the best way to express it is as a low-beta de-risking of a profitable rare-disease asset rather than a high-conviction binary event trade.

Key Decisions for Investors

• Maintain or add to BMRN on pullbacks for a 6-12 month hold: thesis is modest multiple expansion as the accelerated-approval overhang fades; invalidated if 2026 prescription growth slows or payer access worsens.
• Pair trade: long BMRN / short XBI for a quality-biased biotech expression over the next 3-6 months; BMRN has clearer cash-flow durability while XBI remains more exposed to binary pipeline risk.
• Set a watch item on the next VOXZOGO long-term data update and FDA communications: if safety or functional endpoints disappoint, reduce exposure quickly because the stock is priced on regulatory de-risking more than explosive growth.
• No trade in TGT or PPRG from this item; the regulatory catalyst is too idiosyncratic to support a sector-wide or retail spillover view.